Related Experiment Video
Updated: May 10, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients
Johannis A van Rossum1, Anke Vennegoor, Lisanne Balk
1Department of Neurology (MS Center Amsterdam), VU University Medical Center, The Netherlands.
Abstract:
The use of natalizumab in multiple sclerosis has been restricted by the risk of progressive multifocal leukoencephalopathy (PML). JC virus carriership, duration of natalizumab treatment and past immunosuppression are known risk factors. This has allowed for calculated risk assessment for individual patients to be implemented. Not much data are available about the effect of JCV carriership on patient willingness to continue natalizumab. Here, we evaluated the impact of JCV seropositivity on safety feelings, anxiety and treatment continuation for patients treated with natalizumab, using a visual analog scale, the Hospital Anxiety and Depression Scale and a decisional conflict scale. Seropositivity led to an elevated anxiety level for PML (p = 0.004). However, so far only 3% of patients have discontinued natalizumab because of JCV positivity in our cohort.
Insights
JC virus (JCV) positivity increases anxiety in multiple sclerosis patients on natalizumab but rarely impacts treatment continuation. Most patients remain on natalizumab despite JCV seropositivity, indicating manageable risk perception.
Area of Science:
- Neuroimmunology
- Viral Infections
- Clinical Therapeutics
Background:
- Natalalizumab is effective for multiple sclerosis (MS) but carries a risk of progressive multifocal leukoencephalopathy (PML).
- JC virus (JCV) carriership is a primary risk factor for natalizumab-associated PML.
- Limited data exist on how JCV serostatus influences patient decisions regarding natalizumab treatment.
Purpose of the Study:
- To assess the impact of JCV seropositivity on patient anxiety and safety perceptions.
- To evaluate the effect of JCV seropositivity on the willingness to continue natalizumab therapy.
- To analyze decisional conflict related to natalizumab treatment in JCV-positive MS patients.
Main Methods:
- Utilized visual analog scales for safety feelings.
- Employed the Hospital Anxiety and Depression Scale (HADS) to measure anxiety.
- Administered a decisional conflict scale to assess treatment continuation.
- Correlated JCV serostatus with psychological and treatment adherence outcomes.
Main Results:
- JCV seropositivity significantly elevated anxiety levels concerning PML risk (p = 0.004).
- Despite increased anxiety, only 3% of patients in the cohort discontinued natalizumab due to JCV positivity.
- No significant impact on overall treatment continuation was observed solely based on JCV positivity.
Conclusions:
- JCV seropositivity is associated with heightened anxiety regarding PML in MS patients on natalizumab.
- Natalalizumab treatment continuation is generally maintained by patients even when aware of JCV seropositivity.
- Risk-benefit communication strategies may effectively manage patient concerns and support ongoing natalizumab therapy.
Related Concept Videos
Multiple Sclerosis l: Introduction
Cytomegalovirus Disease
Arboviral Encephalitis
Encephalitis l: Introduction
Hypersensitivity Reactions: Immune-Complex Reactions
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
